Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

This marks the fourth such annual challenge backed by the eye health giant, per the announcement. Bausch + Lomb, which recently confirmed it’s exploring the possibility of a sale, is the maker ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ... Neither the safety and effectiveness, nor the effects ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated ... IOL optical design on depth of focus, contrast sensitivity, and subjective visual disturbances ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic atrophy (GA). The early-stage deal breaks down like this: City gets an ...

Bausch + Lomb acquired Whitecap Biosciences to develop therapies for glaucoma and geographic atrophy, aiming to improve visual outcomes. Whitecap's WB007, an alpha-2 adrenergic agonist, showed IOP ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better ... nor the effects of the Aspire IOL optical ...

Jersey City-based Character Biosciences, a company specializing in genetics-guided drug discovery and development, has announced a collaboration with Bausch + Lomb, a leading global eye health company ...